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Antidepressant drugs and generic counselling for
treatment of major depression in primary care:
randomised trial with patient preference arms
Clair Chilvers, Michael Dewey, Katherine Fielding, Virginia Gretton, Paul Miller, Ben Palmer,
David Weller, Richard Churchill, Idris Williams, Navjot Bedi, Conor Duggan, Alan Lee,
Glynn Harrison for the Counselling versus Antidepressants in Primary Care Study Group
Abstract
Objectives To compare the efficacy of antidepressant
drugs and generic counselling for treating mild to
moderate depression in general practice. To
determine whether the outcomes were similar for
patients with randomly allocated treatment and those
expressing a treatment preference.
Design Randomised controlled trial, with patient
preference arms. Follow up at 8 weeks and 12 months
and abstraction of GP case notes.
Setting 31 general practices in Trent region.
Participants Patients aged 18›70 who met research
diagnostic criteria for major depression; 103 patients
were randomised and 220 patients were recruited to
the preference arms.
Main outcome measures Difference in mean Beck
depression inventory score; time to remission; global
outcome assessed by a psychiatrist using all data
sources; and research diagnostic criteria.
Results At 12 months there was no difference between
the mean Beck scores in the randomised arms.
Combining the randomised and patient preference
groups, the difference in Beck scores was 0.4 (95%
confidence interval –2.7 to 3.5). Patients choosing
counselling did better than those randomised to it
(mean difference in Beck score 4.6, 0.0 to 9.2). There
was no difference in the psychiatrist’s overall
assessment of outcome between any of the groups.
221/265 (83%) of participants with a known outcome
had a remission. Median time to remission was shorter
in the group randomised to antidepressants than the
other three groups (2 months v 3 months). 33/221
(15%) patients had a relapse.
Conclusions Generic counselling seems to be as
effective as antidepressant treatment for mild to
moderate depressive illness, although patients
receiving antidepressants may recover more quickly.
General practitioners should allow patients to have
their preferred treatment.
Introduction
Both antidepressants and psychological interventions
have been shown to be effective in patients with major
depression.1 2 The counselling and antidepressants in
primary care study was set up to compare the efficacy
and cost effectiveness of antidepressant drugs and
generic counselling in a naturalistic general practice
setting. The short term outcomes from this study (at
eight weeks) have been published.3 We report here the
outcomes at 12 months.
Participants and methods
Recruitment and treatment
Full details of the methods have been published.3
Briefly, we invited a random sample of 410 general
practices in the Trent health region to enter patients
into the trial. General practitioners recruited partici›
pants and obtained informed consent. Eligible patients
were those aged 18›70 years who met the research
diagnostic criteria (assessed by the general practitioner
using a checklist) for major depression.4 We excluded
patients with psychosis, suicidal tendencies, postnatal
depression, a recent bereavement, or drug or alcohol
misuse. The study was approved by 12 local research
ethics committees.
For patients who agreed to randomisation,
treatment was allocated by telephone with a randomi›
sation strategy using blocks of four stratified by
practice. Patients who refused randomisation but
agreed to participate in the patient preference trial
were given their choice of treatment. Treatment and
follow up were identical in the randomised and patient
preference groups.
We provided general practitioners with written
guidelines on routine drug treatment of depression.
Patients in the counselling arms were given six sessions
by experienced counsellors, who adopted the counsel›
ling approach that they believed to be most suitable.
Data collection and follow up
All patients completed the Beck depression inventory5
and SF›36 questionnaire at enrolment.6 7 At the follow
up visits eight weeks and 12 months after enrolment,
the general practitioner completed a form that
included the research diagnostic criteria and the
patient was asked to complete a form including the
Beck depression inventory and SF›36. Patients who did
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not keep their follow up appointments were asked to
complete the forms at home.
We also abstracted information from general prac›
titioners’ case notes. This included general practitioner
appointments; psychiatric and other hospital referrals;
inpatient treatment; prescribed treatments (both
antidepressants and other drugs); and referral to coun›
sellors outside the study protocol.
Outcome measures
The main outcome measures at 12 months were Beck
depression inventory score, time to remission,8 9 global
outcome (classified as good, moderate, poor, or
unknown), and research diagnostic criteria. Remission
was defined as a score of less than 4 on the research
diagnostic criteria, a Beck score of less than 10, or clear
documentation in the general practitioner’s notes that
the patient was well. Relapse was defined as deteriora›
tion within six months of remission, and recurrence as
deterioration after six months of remission.
Global outcome was assessed by a psychiatrist (NB)
blind to treatment allocation using the research
diagnostic criteria, Beck score, and general practition›
ers’ notes. If the research diagnostic criteria and Beck
scores were not available, global outcome was
estimated from the case notes. The outcome was
considered good if the patient responded to treatment
within eight weeks and then remained well; moderate if
the patient was slow to respond but then remained well
or was well initially and then became unwell; and poor
if the patient remained depressed throughout. The cri›
teria for being well were the same as the criteria for
remission.
We masked abstracts of general practitioners’ notes
by erasing words identifying the treatment group. To
check the effectiveness of the masking, the assessor
recorded the treatment group to which she thought
that the first 20 patients had been allocated.
Patients with unknown outcomes or time to remis›
sion were independently reviewed by two senior
psychiatrists (CD, AL). For assessments based on Beck
scores and where the scores at eight weeks and 12
months were both high, it was assumed that the patient
had remained unwell in the intervening period; if the
patient was not in remission at eight weeks but was in
remission at 12 months, the time to remission was
taken as 12 months in all comparative analyses.
The secondary outcome measures were change in
SF›36 score, number of psychiatric referrals, number of
hospital admissions, and suicide.
Statistical analysis
We conducted analyses to compare the randomised
groups and investigate the interaction between
treatment outcome and whether the patients were ran›
domised. Before the study started we decided that if
there was no evidence of interaction, the randomised
and patient preference groups would be combined to
investigate treatment outcome in all patients. Because
the study had low power to detect interactions, we
would also do a stratified analysis. If an interaction was
found between treatment and preference interaction
we would do only a stratified analysis.
We analysed all data using SPSS version 8. We
investigated differences in baseline characteristics and
outcome measures between the groups using descrip›
tive statistics, unpaired t tests, ÷2 tests, and Fisher’s exact
test. The analyses stratified by randomised or patient
preference status used Mantel›Haenszel techniques.
The time to remission was analysed by the Kaplan›
Meier method, and differences were tested with the
logrank test.10 11 We censored observations at the last
recorded visit to the general practitioner.
Study size
We originally planned to use a binary outcome: recov›
ery or not, based on change in Beck score. With a
recovery rate of 50% in one group and 40% in the
other, two sided significance of 0.05, and power of 0.90,
we required 400 patients in each arm. Because recruit›
ment was slow, we resized the study using the
difference in mean Beck scores at 12 months as the
outcome. Based on a clinically important difference
between the groups in mean Beck scores of 5 points,
and assuming a standard deviation of 8.3 with two
sided significance of 0.05, we required 44 patients per
arm for power of 80% and 60 per arm for power of
90%.
Results
Response rates
The figure shows the numbers of patients recruited
and followed up. There was no systematic difference
between the proportions of patients completing the 12
month questionnaire in terms of treatment or whether
they were randomised (P = 0.34 for heterogeneity
between the four groups). Sixty five (63%) patients in
the randomised trial completed the Beck depression
inventory and SF›36 at 12 months compared with 142
(65%) in the patient preference trial. The proportions
of patients in each group who kept their 12 month
appointment differed (P = 0.01), with attendance rang›
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ing between 25% for patients choosing antidepressants
and 53% for those randomised to antidepressants.
We abstracted the general practitioner’s notes for
96% (99/103) of patients in the randomised trial and
96% (212/220) in the patient preference. There was
sufficient information to carry out the psychiatrist’s
overall assessment on 79% (81/103) of patients in the
randomised trial and 74% (163/220) in the patient
preference trial.
Patient characteristics at entry
The patients were predominantly women, there were
roughly equal numbers in social classes I/II, III,
and IV/V, and 57% were married (table 1). Patients
preferring counselling were less severely depressed
than the randomised patients or those preferring anti›
depressants.3
Beck inventory scores at 12 months
Mean Beck scores did not differ significantly between
the two groups in the randomised controlled trial
(P = 0.49, table 2). There was no evidence for an inter›
action between treatment and preference (P = 0.6) so
we combined the randomised and patient preference
groups. Mean Beck scores were similar in counselled
patients and those receiving antidepressants (13.2 v
12.8, 95% confidence interval for difference − 2.7 to
3.5).
We investigated the effect of patient preference by
comparing the randomised and patient preference
groups for the two treatments separately. There was no
difference in the mean Beck scores for the patients
treated with antidepressants (mean difference 3.1, 95%
confidence interval –1.8 to 7.8), but the patients choos›
ing counselling did better than those randomised to
counselling (mean difference 4.6, 95% confidence
interval 0.0 to 9.2).
Global outcome and time to remission
We found no differences in global outcome between
the randomised or patient preference trials when out›
come was split into good or moderate versus poor
(table 3). Stratification by randomised or patient
preference status gave similar outcomes for antide›
pressants and counselling (Mantel Haenszel P = 0.63).
Similar results were obtained by splitting the outcomes
into good versus moderate or poor. The treatment
allocations were guessed correctly by the assessor in
nine of the 20 sets of notes, indicating that the masking
was satisfactory.
Overall, 68% (221/323) of patients had a remission
or 83% (221/265) of those with a known outcome. The
proportions of patients who had a remission were
similar in each group (table 3). Median time to
remission was three months in all groups except the
group randomised to antidepressants, where the
median time to remission was two months (comparing
randomised groups logrank statistic 2.74, P = 0.1;
pooled logrank statistic for randomised and patient
preference trials 0.82, P = 0.36). Thirty three (15%) of
Table 1 Summary of baseline characteristics. Values are numbers (percentages) unless stated otherwise
Characteristic
Randomised Patient preference P value for
comparison of
4 groups
Counselling
(n=52)
Antidepressants
(n=51) P value
Counselling
(n=140)
Antidepressants
(n=80) P value
Men 16 (31) 8 (16) 0.12 36 (26) 21 (26) 1.00 0.34
Mean (SD) age 37.3 (11.2) 38.4 (11.8) 0.60 36.4 (10.1) 38.1 (12.7) 0.27 0.60
Married* 17/35 (49) 23/36 (64) 0.29 58/101 (57) 25/45 (56) 1.00 0.63
Living alone* 7/35 (20) 2/36 (6) 0.14 11/101 (11) 5/45 (11) 1.00 0.29
Family history of depression* 15/34 (44) 19/36 (53) 0.47 51/94 (54) 21/43 (49) 0.56 0.76
Mean (SD) age at onset* 33.3 (24.2) 35.6 (18.6) 0.65 35.1 (20.7) 34.1 (20.6) 0.79 0.96
Social class*:
I or II 6/30 (20) 12/31 (39)
0.24
38/91 (42) 12/41 (29)
0.28 0.30III non›manual or manual 12/30 (40) 11/31 (35) 34/91 (37) 16/41 (39)
IV or V 12/30 (40) 8/31 (26) 19/91 (21) 13/41 (32)
Beck inventory score:
Mean (SD) 27.1 (8.0) 27.0 (8.0) 0.97 25.8 (7.7) 25.4 (9.5) 0.78 0.57
Not known 2 2 6 8
Research diagnostic criteria score:
4 or 5 19 (37) 14 (27)
0.44
59 (42) 22 (28)
0.04 0.106›8 32 (62) 36 (71) 81 (58) 58 (73)
Not known 1 (2) 1 (2) 0 0
General practitioner’s rating:
Mild 12 (24) 10 (19)
0.29
45 (32) 10 (13)
00.001 0.004
Moderate 33 (66) 31 (61) 87 (62) 62 (78)
Severe 3 (6) 8 (16) 5 (4) 8 (10)
Not known 2 (4)† 2 (4) 3 (2) 0
*Some patients did not have the telephone interview immediately after recruitment.
†Data were not completed by the general practitioner for two further patients.
Table 2 Scores on Beck depression inventory scale at 12 months
Counselling Antidepressants
Difference (95% CI) P valueNo of patients Mean (SD) score No of patients Mean (SD) score
Randomised patients 31 16.7 (11.5) 34 14.6 (13.1) 2.1 (−4.0 to 8.2) 0.49
All patients* 127 13.2 (11.3) 80 12.8 (10.7) 0.4 (−2.7 to 3.5) 0.81
*Score adjusted for patient preference or randomised group and baseline score for research diagnostic criteria: P=0.34.
Primary care
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the 221 patients had a relapse. There were no
differences between the groups.
Research diagnostic criteria scores
Of the randomised patients who kept their 12 month
follow up, nine (47%) in the counselling group were no
longer depressed compared with 21 (78%) in the anti›
depressant group (P = 0.07, table 4). When we assumed
that all those failing to attend had recovered, then 81%
in the counselling group and 88% in the antidepres›
sant group were no longer depressed. The figures
when we assumed that patients failing to attend were
treatment failures were 17% and 41% respectively
(P = 0.01).
In the patient preference trial, 48 (80%) patients
choosing counselling and 17 (85%) choosing anti›
depressants had recovered at 12 months (P = 0.87). If
missed appointments were assumed to be treatment
successes the outcomes were similar, but if all missed
appointments were treatment failures, patients choos›
ing counselling would do better than those choosing
antidepressants.
Secondary outcomes
There were no differences in scores between patients
randomised to counselling or antidepressants on any
of the SF›36 domains (data not shown). The scores
were also similar when the randomised and preference
arms were combined. Patients who chose counselling
did consistently better than those randomised to coun›
selling on all dimensions of the SF›36.
Two (2%) randomised patients and 15 (7%) prefer›
ence patients were referred for outpatient assessment
(P = 0.1, table 3). Few patients received inpatient treat›
ment relating to depression, and there were no
differences between the groups. There were no
differences in the proportions of patients attending as
inpatients for unrelated conditions.
One 46 year old man committed suicide two
months after enrolling in the study in the patient pref›
erence antidepressants arm. His Beck score at entry
was 43. In accordance with the study protocol, the
patient’s general practitioner was notified of this score.
Discussion
The data from our randomised controlled trial suggest
that at 12 months follow up generic counselling and
antidepressants are equally effective in patients with
mild to moderate depression; remission rates are
impressive with both treatments. These conclusions are
based on the Beck depression inventory scores and the
overall assessment by the psychiatrist. Patients treated
with antidepressants recovered more quickly than
those receiving counselling. A recent randomised
comparison of non›directive counselling and general
practitioner care found that at four months the
counselled patients had improved more than those
receiving usual care, but by 12 months there were no
differences between the groups.12 The results of the
research diagnostic criteria questionnaire are less clear.
They are based on less than 50% of patients, the
number who returned to their general practitioner at
12 months, and the sensitivity analysis gave divergent
results depending on the assumptions made. Choice of
treatment seemed to be beneficial, but this applied only
to counselling. This finding should be treated with
Table 3 Global outcome, remission, and relapse in randomised and patient preference groups. Values are numbers (percentages) of
patients. Totals exclude missing data but include patients in whom outcome was uncertain
Randomised patients Patient preference P value for
Mantel Haenszel
÷2 test
Counselling
(n=52)
Antidepressants
(n=51) P value
Counselling
(n=140)
Antidepressants
(n=80) P value
Global outcome:
Good or moderate 29 (56) 33 (65) 0.854* 90 (64) 54 (68) 0.803* 0.626
Good 13 (25) 21 (41) 0.196* 50 (36) 22 (28) 0.191* 0.868
Ever remitted 33/48 (69) 39/50 (78) 0.633* 95/129 (74) 54/78 (69) 0.872* 0.739 (yes v no)
Ever relapsed 5/33 (15) 4/39 (10) 0.820† 18/95 (19) 6/54 (11) 0.615* 0.455
Outpatient psychiatric referral 2 (4) 0 0.505† 10 (7) 5 (6) 0.927* 0.668
Inpatient treatment for
depression
1‡ (2) 2 (4) 0.970† 2 (1) 0 0.849† §
Other inpatient treatment 6 (12) 8 (16) 0.711* 22 (16) 14 (18) 0.706* 0.498
*÷2 test.
†Fisher’s exact test.
‡One patient attended twice.
§Invalid because of small numbers.
Table 4 Comparison of outcome at 12 months on research diagnostic criteria in patients receiving counselling or antidepressants
Research diagnostic criteria score
Randomised Patient preference
No (%)
counselling
No (%)
antidepressants
÷2 test
(P value)
No (%)
counselling
No (%)
anti›depressants
÷2 test
(P value)
Omitting patients with missed visits:
>4 10 (53) 6 (22) 3.30 (0.07) 12 (20) 3 (15) 0.03 (0.87)
<4 9 (47) 21 (78) 48 (80) 17 (85)
Assuming missed visit is treatment success:
>4 10 (19) 6 (12) 0.60 (0.44) 12 (9) 3 (4) 1.18 (0.28)
<4 42 (81) 45 (88) 128 (91) 77 (96)
Assuming missed visit is treatment failure:
>4 43 (83) 30 (59) 6.00 (0.01) 92 (66) 63 (79) 3.55 (0.06)
<4 9 (17) 21 (41) 48 (34) 17 (21)
Primary care
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caution as the power of the study to detect interactions
was low.
The larger numbers of patients choosing counsel›
ling in this trial suggests that patients prefer
counselling to antidepressants.3 A survey of people
attending general practice had similar findings.13 A
higher proportion of patients in the patient preference
trial than in the randomised trial were referred to out›
patients. This may reflect the slightly higher proportion
of people in social classes I and II in the patient prefer›
ence trial (38% v 30% in randomised trial). Most
patients presenting with depression in primary care,
however, will not be referred to secondary care.
Several caveats must be taken into account when
interpreting these data. Firstly, we had difficulty
recruiting patients into the randomised controlled trial.
The patient preference arms, although increasing the
power of the study, tend to make our findings less robust.
Secondly, the counselling offered in the study was of a
high standard; patients were referred within two weeks,
and all the counsellors were experienced. Thirdly,
although we found some benefit associated with choice,
we did not investigate the effect of giving an alternative
treatment to those with a specific preference.
What conclusions should commissioners and gen›
eral practitioners draw from this study? Firstly, that
both counselling and antidepressant drugs are
effective, but antidepressants may result in more rapid
recovery. Secondly, that given the choice more patients
with depression will choose counselling and those who
choose antidepressants are likely to be more severely
depressed. We recommend that general practitioners
should allow patients to have their choice of treatment.
However, if the patient does not have a preference,
antidepressant drugs should be prescribed because
counselling is a scarce resource that is best reserved for
those patients who express a preference for it.
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What is already known on this topic
Antidepressants and specific psychological
interventions are effective in major depression.
Generic counselling has not previously been
compared with antidepressants in primary care
What this study adds
12 months after starting treatment, generic
counselling is as effective as antidepressants
Patients treated with antidepressants may recover
more quickly
Given a choice, more patients opt for counselling
Patients who choose counselling may benefit more
than those with no strong preference
Primary care
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